FDA approves first DNA-based test for colon cancer

Published on NewsOK Modified: August 11, 2014 at 5:43 pm •  Published: August 11, 2014
Advertisement
;

WASHINGTON (AP) — The Food and Drug Administration on Monday approved the first screening test for colon cancer that uses patients' DNA to help spot potentially deadly tumors and growths.

The Cologuard test from Exact Sciences detects irregular mutations in stool samples that can be an early warning sign of cancer. Patients who test positive for the mutations should undergo a colonoscopy to confirm the results.

Doctors have long used stool tests to look for hidden blood that can be a warning sign of tumors and precancerous polyps.

But company studies of Cologuard showed that it was more accurate at detecting cancerous tumors and worrisome polyps than traditional stool blood tests. Cologuard detected 92 percent of colon cancers and 42 percent of advanced polyps in a study of 10,000 patients, while traditional blood screening only detected 74 percent of cancers and 24 percent of advanced polyps.

The new test was not superior on all counts though. Cologuard was less accurate than older blood tests at correctly ruling out cancer, reporting more growths when none were actually present.

The approval has the potential to reshuffle current medical practice, though FDA officials stressed Monday that DNA-based stool screening has not been endorsed by federal medical advisers who set screening guidelines. A spokeswoman for Exact Sciences, which is based in Madison, Wisconsin, said the new test would cost $599 per patient. That compares to about $25 for a traditional stool blood test.

Exact Sciences' CEO Kevin Conroy said that Cologuard's cost is justified considering that the U.S. spends over $14 billion annually treating cases of colon cancer that go undetected.

Continue reading this story on the...